在2025年的一项研究中,在未接受治疗的CLL患者中,包括高风险患者中,Sonrotoclax与BRUKINSA实现了近乎完全的缓解. Sonrotoclax with BRUKINSA achieved near-complete remission in untreated CLL patients, including high-risk cases, in a 2025 study.

在2025年美国卫生健康委员会年会上,BeOne药物公司报告说,在未接受治疗的CLL患者,包括具有高风险遗传特征的患者中,sonrotoclax与BRUKINSA结合实现了快速和持续的不可检测的最小残留疾病 (uMRD). At the 2025 ASH Annual Meeting, BeOne Medicines reported that sonrotoclax combined with BRUKINSA achieved rapid and sustained undetectable minimal residual disease (uMRD) in treatment-naive CLL patients, including those with high-risk genetic features. 在一项第1/2阶段的研究中,98%的病人在96周前达到4 uMRD4,中间时间仅为4周,总体答复率为100%。 In a Phase 1/2 study, 98% of patients reached uMRD4 by 96 weeks, with a median time to uMRD4 of just weeks, and a 100% overall response rate. 在R/R MCL中,冠状单一疗法在高风险分组中显示52.4%的总体响应率和持久响应率,支持美国可能的加速批准。 In R/R MCL, sonrotoclax monotherapy showed a 52.4% overall response rate and durable responses in high-risk subgroups, supporting potential U.S. accelerated approval. 数据突显出索罗托康拉克在B细胞恶性肿瘤中的承诺。 The data highlight sonrotoclax’s promise across B-cell malignancies.